GLP-1 Medications and Psoriasis: What the Research Shows

GLP-1 medications like semaglutide and tirzepatide are showing early promise for reducing psoriasis severity, with several clinical studies published in 2024 and 2026 documenting measurable improvements in skin inflammation alongside weight loss.

*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and is not medical advice. Clinical research cited here was conducted using FDA-approved pharmaceutical formulations unless otherwise noted. Compounded GLP-1 medications have not been studied in the psoriasis trials described in this article. Individual results vary significantly. If you have psoriasis, psoriatic arthritis, or another immune-mediated condition, consult your dermatologist or rheumatologist before starting, stopping, or changing any medication.*

---

Psoriasis affects between 2 and 3 percent of the US population. It is not simply a skin condition. Behind the plaques and scaling lies a systemic inflammatory process driven by immune dysregulation, and for many patients that immune burden connects directly to metabolic health. Excess weight worsens psoriasis. Psoriasis worsens cardiovascular risk. And for roughly 30 percent of people with psoriasis, the inflammation eventually extends to the joints in a condition called psoriatic arthritis.

GLP-1 receptor agonists have reshaped what is possible in weight management. They have also revealed, somewhat unexpectedly, a range of anti-inflammatory effects that are now drawing serious attention from dermatologists and rheumatologists. A growing body of research suggests these medications may do more than reduce body weight in people with psoriasis. They may directly influence the immune pathways driving the disease.

Understanding Psoriasis as a Systemic Inflammatory Disease

Psoriasis is classified as an immune-mediated inflammatory disease. The core problem is a cycle of immune overactivation in which T-lymphocytes mistakenly attack skin cells, triggering accelerated skin cell turnover and the chronic inflammation visible as characteristic plaques, redness, and scaling.

Key drivers include elevated levels of cytokines including TNF-alpha, IL-17, and IL-23. These same cytokines, when chronically elevated, contribute to metabolic dysfunction, cardiovascular disease, and joint inflammation.

A 2026 review in *Nature Reviews Rheumatology* (Haberman RH et al., 2026, [PMID: 41286370](https://pubmed.ncbi.nlm.nih.gov/41286370/)) examined the obesity-inflammation axis in psoriatic disease in depth. The authors found that adipose tissue in people with psoriasis behaves differently from fat tissue in healthy controls. It produces higher concentrations of pro-inflammatory adipokines, particularly leptin and resistin, and lower concentrations of the anti-inflammatory protein adiponectin. This state of "adipose inflammation" actively amplifies the dermal and synovial inflammation characteristic of psoriatic disease.

Excess weight is not a passive bystander in psoriasis. It sustains the immune dysfunction driving the disease.

Why Weight and Psoriasis Are Deeply Linked

The relationship between body weight and psoriasis severity is bidirectional and well documented. Obesity is a recognized risk factor for developing psoriasis, and in patients who already have it, higher BMI correlates with:

• More severe disease (measured by PASI, the Psoriasis Area and Severity Index)
• Reduced response to biologic medications like adalimumab and ustekinumab
• Higher rates of psoriatic arthritis development
• Greater cardiovascular and metabolic comorbidity burden

This creates a clinical challenge. Many first-line psoriasis treatments work less well in patients with obesity. And medications used to treat psoriasis, particularly corticosteroids, can themselves cause weight gain, perpetuating the cycle.

This is the context in which researchers began asking whether GLP-1 medications, with their ability to produce significant sustained weight loss, might also influence psoriasis disease activity.

How GLP-1 Medications May Affect Psoriasis

The potential mechanisms are both indirect and direct.

The Weight Loss Pathway

Achieving even 5 to 10 percent weight reduction has been shown to improve psoriasis severity scores in patients with obesity, independently of other treatments. GLP-1 medications produce sustained weight loss of 15 to 22 percent in large clinical trials, meaning the weight-loss benefit alone could translate meaningfully into psoriasis improvement for many patients.

Reducing adipose tissue also reduces the volume of pro-inflammatory adipokines circulating in the bloodstream, with downstream effects on the cytokine environment in both skin and joints.

Direct Anti-Inflammatory Effects

Beyond weight loss, GLP-1 receptors are expressed on immune cells, including T-lymphocytes and macrophages, that play central roles in psoriatic inflammation. When GLP-1 receptors on these cells are activated, the result is reduced production of TNF-alpha and IL-6, two key drivers of both psoriatic skin inflammation and joint inflammation.

A 2026 review in *Frontiers in Immunology* (Ciancio G et al., 2026, [PMID: 42131335](https://pubmed.ncbi.nlm.nih.gov/42131335/)) synthesized the emerging evidence specifically for psoriasis and psoriatic arthritis. The authors identified two parallel mechanisms: the weight-loss-mediated reduction in adipose inflammation, and direct immunomodulatory effects via GLP-1 receptor activation on immune cells. They concluded that GLP-1 receptor agonists represent a mechanistically rational option for psoriatic disease, particularly in patients with comorbid obesity.

What Clinical Studies Show

Semaglutide and Psoriatic Lesion Reduction

The most rigorous human evidence comes from a 2025 open-label randomized clinical trial published in *Biomolecules* (Petković-Dabić J et al., 2025, [PMID: 39858442](https://pubmed.ncbi.nlm.nih.gov/39858442/)). Researchers enrolled obese patients with type 2 diabetes and moderate-to-severe psoriasis, randomizing them to receive semaglutide or standard diabetes management without a GLP-1 medication.

At 24 weeks, the semaglutide group showed statistically significant reductions in PASI scores compared to the control group. The psoriasis improvements were observed alongside the expected metabolic changes, including lower HbA1c and body weight.

Importantly, the magnitude of psoriasis improvement correlated with the degree of weight loss, supporting the hypothesis that body weight reduction is part of the mechanism. Some patients showed psoriasis improvements that exceeded what weight loss alone would predict, suggesting a direct immunomodulatory contribution.

An earlier case series (Malavazos AE et al., 2023, [PMID: 37551923](https://pubmed.ncbi.nlm.nih.gov/37551923/)) published in *Endocrinology, Diabetes and Metabolism Case Reports* documented semaglutide improving both epicardial fat inflammation and psoriasis severity in patients with abdominal obesity and type 2 diabetes, providing earlier mechanistic support for the RCT findings.

Tirzepatide in Psoriasis Patients

A 24-week real-world study published in *Dermatology and Therapy* in July 2026 (Gisondi P et al., 2026, [PMID: 42240733](https://pubmed.ncbi.nlm.nih.gov/42240733/)) examined the effects of tirzepatide in patients with psoriasis and comorbid obesity. The study tracked both metabolic parameters and psoriasis disease activity.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, produced significant reductions in body weight, waist circumference, and insulin resistance. Alongside these metabolic improvements, investigators documented reductions in psoriasis severity scores in a meaningful proportion of participants. Metabolic improvement and skin improvement appeared to track together, consistent with the hypothesis that reducing adipose-driven inflammation benefits the dermal environment.

Outcomes at Scale: GLP-1 Use Across Psoriasis Populations

Beyond direct psoriasis severity measurements, a large-scale cohort study published in the *British Journal of Dermatology* (Olbrich H et al., 2026, [PMID: 40897378](https://pubmed.ncbi.nlm.nih.gov/40897378/)) examined broad health outcomes in thousands of psoriasis patients who used GLP-1 receptor agonists compared to those who did not.

GLP-1 receptor agonist use was associated with significantly reduced risks across several clinically important outcomes:

• All-cause mortality
• Major adverse cardiovascular events
• Psychiatric comorbidities, including depression (which disproportionately affects people with psoriasis)
• Hospitalizations related to psoriatic disease

These findings cannot prove causation, but they reflect the real-world trajectory of psoriasis patients who receive GLP-1 medications, and the direction of evidence is consistently favorable.

GLP-1 Medications and Psoriatic Arthritis

Psoriatic arthritis represents a distinct and often underrecognized complication of psoriasis. Roughly 30 percent of people with psoriasis develop joint inflammation, stiffness, and potentially erosive joint damage. The disease is driven by many of the same cytokine pathways that fuel skin involvement, particularly IL-17 and TNF-alpha.

A scoping review published in the *Journal of Clinical Rheumatology* (Karacabeyli D et al., 2024, [PMID: 36870080](https://pubmed.ncbi.nlm.nih.gov/36870080/)) systematically examined published evidence on GLP-1 receptor agonists in patients with inflammatory arthritis and psoriasis. The review found emerging signals that GLP-1 medications may reduce joint inflammation in the psoriatic arthritis setting, alongside the skin benefits described above.

A subsequent review in *Nature Reviews Rheumatology* (Karacabeyli D et al., 2025, [PMID: 41034339](https://pubmed.ncbi.nlm.nih.gov/41034339/)) expanded on these findings across the full breadth of evidence for GLP-1 medications in inflammatory arthritis conditions. The authors identified that GLP-1 receptor activation reduces synovial inflammation through mechanisms including decreased macrophage-driven cytokine production and improved metabolic conditions in joint tissue.

For patients with both psoriasis and psoriatic arthritis, the possibility of a single medication addressing weight, skin inflammation, and joint inflammation simultaneously represents a potentially significant clinical development. The evidence base is still emerging, and no GLP-1 medication is currently approved to treat psoriasis or psoriatic arthritis.

Who Might Benefit Most

Based on current evidence, researchers believe GLP-1 medications are most likely to provide meaningful psoriasis benefit in patients who have:

Comorbid obesity. The evidence consistently comes from studies of patients with both psoriasis and elevated BMI. Whether GLP-1 medications provide meaningful psoriasis benefits in patients without obesity has not yet been established.

Moderate to severe psoriasis. Measurable improvements in psoriasis scores come predominantly from studies of patients with moderate-to-severe disease, where there is meaningful room for improvement.

Suboptimal biologic response. For patients who have tried biologic medications and seen incomplete responses, the possibility that weight loss and anti-inflammatory effects from a GLP-1 medication might enhance the effectiveness of existing treatment is clinically relevant. Obesity is a known driver of biologic resistance in psoriasis.

Psoriatic arthritis with metabolic comorbidities. The joint benefits of GLP-1 medications appear to be mediated partly by systemic inflammation reduction and partly by metabolic improvement. Patients with active joint disease and metabolic syndrome may represent a particularly addressable group.

Important Considerations

These medications are not treatments for psoriasis. Compounded semaglutide and tirzepatide are not FDA-approved for psoriasis or psoriatic arthritis. They are approved for weight management and type 2 diabetes. The observed skin and joint benefits appear to be secondary effects of weight loss and systemic inflammation reduction, not a direct antipsoriatic mechanism validated in pivotal trials.

Existing therapies remain the standard of care. If you have moderate to severe psoriasis, your dermatologist will likely recommend a biologic or small-molecule medication targeting specific cytokine pathways. GLP-1 medications, when used, would typically be considered alongside, not instead of, established treatment.

Weight management matters regardless. Even outside of GLP-1 medications specifically, the evidence supporting weight management as a component of psoriasis care is strong. Interventions that reduce body weight improve psoriasis outcomes and biologic response.

Drug interactions and side effects require oversight. GLP-1 medications cause gastrointestinal side effects in many patients, particularly during dose escalation. Anyone managing psoriasis with systemic medications or biologics should discuss any new medication with their full care team.

Psoriatic arthritis requires a rheumatologist. If you have joint symptoms alongside psoriasis, evaluation by a rheumatologist is important before adding any new medication that might influence joint inflammation. Psoriatic arthritis causes irreversible joint damage if undertreated.

Frequently Asked Questions

Can semaglutide reduce psoriasis plaques? Studies show semaglutide can reduce psoriasis severity scores in obese patients with type 2 diabetes, but it does not clear plaques the way targeted biologic medications do. The improvements are clinically meaningful but generally not complete remission.

Does tirzepatide help with psoriasis? A 2026 real-world study found tirzepatide improved both metabolic parameters and psoriasis disease activity in patients with psoriasis and obesity. The evidence is early but consistent with findings from semaglutide studies.

Is GLP-1 medication a replacement for biologic therapy in psoriasis? No. GLP-1 medications are not approved to treat psoriasis and are not a substitute for established biologic therapies. They may be useful as complementary interventions for patients who also need weight management.

Can GLP-1 medications help with psoriatic arthritis? Early evidence from scoping reviews and mechanistic studies suggests GLP-1 medications may reduce joint inflammation in psoriatic arthritis patients, particularly those with obesity. This is an active area of research, and no GLP-1 medication is approved for psoriatic arthritis.

Should I discuss GLP-1 medications with my dermatologist if I have psoriasis and obesity? Yes. Given the emerging evidence, it is a reasonable topic to raise, particularly if you have been struggling to manage your weight and your psoriasis has been difficult to control. Any decision should involve your full care team.

Ready to Explore Your Options?

If you have psoriasis, comorbid obesity, and are interested in whether a GLP-1 medication might be appropriate for you, speaking with a knowledgeable provider is the right first step.

Ready to explore your options? [Check your eligibility](/assessment) for a telehealth evaluation with Prescriva's clinical team.

---

Sources

1. Petković-Dabić J, et al. Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial. *Biomolecules*. 2025 Jan. [PMID: 39858442](https://pubmed.ncbi.nlm.nih.gov/39858442/)
2. Gisondi P, et al. Effects of Tirzepatide on Metabolic Parameters in Patients with Psoriasis and Obesity: 24-Week Real-World Study. *Dermatology and Therapy*. 2026 Jul. [PMID: 42240733](https://pubmed.ncbi.nlm.nih.gov/42240733/)
3. Olbrich H, et al. Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study. *British Journal of Dermatology*. 2026. [PMID: 40897378](https://pubmed.ncbi.nlm.nih.gov/40897378/)
4. Haberman RH, et al. The obesity-inflammation axis in psoriatic disease: mechanisms and therapeutic strategies. *Nature Reviews Rheumatology*. 2026. [PMID: 41286370](https://pubmed.ncbi.nlm.nih.gov/41286370/)
5. Ciancio G, et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. *Frontiers in Immunology*. 2026. [PMID: 42131335](https://pubmed.ncbi.nlm.nih.gov/42131335/)
6. Karacabeyli D, et al. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. *Journal of Clinical Rheumatology*. 2024. [PMID: 36870080](https://pubmed.ncbi.nlm.nih.gov/36870080/)
7. Karacabeyli D, et al. Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions. *Nature Reviews Rheumatology*. 2025. [PMID: 41034339](https://pubmed.ncbi.nlm.nih.gov/41034339/)
8. Malavazos AE, et al. Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes. *Endocrinology, Diabetes and Metabolism Case Reports*. 2023. [PMID: 37551923](https://pubmed.ncbi.nlm.nih.gov/37551923/)